Dynavax Technologies | DVAX

Dynavax Technologies traded at $9.81 this Wednesday March 29th, increasing $0.05 or 0.51 percent since the previous trading session. Looking back, over the last four weeks, Dynavax Technologies gained 3.73 percent. Over the last 12 months, its price fell by 10.82 percent. Looking ahead, we forecast Dynavax Technologies to be priced at 9.55 by the end of this quarter and at 8.66 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
AbbVie 158.00 -0.25 -0.16% -3.51%
Adma Biologics 3.27 0.06 1.87% 79.67%
Agenus 1.56 0.08 5.41% -40.46%
Amgen 241.03 2.55 1.07% -0.63%
AstraZeneca 11,166.00 32.00 0.29% 9.90%
AstraZeneca 68.64 0.04 0.06% 2.26%
Biogen 274.01 3.76 1.39% 29.84%
BioMarin Pharmaceutical 94.20 2.76 3.02% 20.94%
Bristol-Myers Squibb 68.18 -0.02 -0.03% -7.51%
Chimerix 1.24 0.05 4.20% -73.10%
Dynavax Technologies 9.81 0.05 0.51% -10.82%
Gilead Sciences 81.29 0.32 0.40% 36.74%
Glaxosmithkline 35.06 -0.04 -0.11% -19.77%
Aceragen Inc 2.16 -0.02 -0.92% -75.72%
Merck & Co 104.92 -0.61 -0.58% 27.33%
Neurocrine Biosciences 97.10 0.69 0.72% 5.03%
Minerva Neurosciences 1.71 0.02 1.18% 102.34%
Nektar Therapeutics 0.73 0.02 2.22% -86.96%
Novartis 82.93 -0.54 -0.65% 1.57%
Pfizer 40.25 0.26 0.65% -22.25%
Regeneron Pharmaceuticals 819.35 -7.62 -0.92% 17.31%
Roche Holding 258.85 1.90 0.74% -30.19%
Sarepta Therapeutics 136.56 2.66 1.99% 73.76%
TG Therapeutics 14.85 0.20 1.37% 51.22%
Vertex Pharmaceuticals 314.24 0.99 0.32% 20.41%

Indexes Price Day Year
USND 11926 210.16 1.79% -17.42%
US2000 1772 18.97 1.08% -15.28%

Dynavax Technologies
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company that is focused on developing and commercializing novel vaccines. The Company's products include HEPLISAV-B and CpG 1018TM. The HEPLISAV-B is for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The Company also manufactures and sells CpG 1018TM, the adjuvant used in HEPLISAV-B. The Company also engaged in developing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships.